Preclinical Studies of Noncharged Oxime Reactivators for Organophosphate Exposure

Journal of Biochemical and Molecular Toxicology

Volumn 28, Issue 1, 2014, Pages 23-31

  Okolotowicz, Karl J ^a   Dwyer, Mary ^a   Smith, Emily ^a   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Amidine oxime reactivators; Cholinesterases; Organophosphate; Oximes; Pharmacokinetics; Reactivation

Indexed keywords

AMIDINE; CHOLINESTERASE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; N 1 (DIMETHYLAMINO) 2 (HYDROXYIMINO)ETHYLIDENE)BUTAN 1 AMINIUM CHLORIDE; ORGANOPHOSPHATE; OXIME; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG SAFETY; DRUG STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEOPHILICITY; ORGANOPHOSPHATE POISONING; PH; RAT;

ANIMALIA;

AMIDINE-OXIME REACTIVATORS; CHOLINESTERASES; ORGANOPHOSPHATE; OXIMES; PHARMACOKINETICS; REACTIVATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; ORGANOPHOSPHATES; OXIMES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84891625711     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.21519     Document Type: Article

References (30)

1. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993;58(1):51-66.
2. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet 2008;371(9612):597-607.
3. Eddleston M, Dawson AH. Triage and clinical management of patients with acute pesticide self-poisoning presenting to small rural hospitals. Clin Toxicol (Phila) 2012;50(6):455-457.
4. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill; 2001. pp 175-191.
5. Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 2004;38:151-216.
6. Balali-Mood M, Shariat M. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J Physiol Paris 1998;92(5-6):375-378.
7. Demar JC, Clarkson ED, Ratcliffe RH, Campbell AJ, Thangavelu SG, Herdman CA, Leader H, Schulz SM, Marek E, Medynets MA, Ku TC, Evans SA, Khan FA, Owens RR, Nambiar MP, Gordon RK. Pro-2-PAM therapy for central and peripheral cholinesterases. Chem Biol Interact 2010;187(1-3):191-198.
8. Bedford CD, Howd RA, Dailey OD, Miller A, Nolen HW III, Kenley RA, Kern JR, Winterle JS. Nonquaternary cholinesterase reactivators. 3. 3(5)-Substituted 1, 2, 4-oxadiazol-5(3)-aldoximes and 1, 2, 4-oxadiazole-5(3)-thiocarbohydroximates as reactivators of organophosphonate-inhibited eel and human acetylcholinesterase in vitro. J Med Chem 1986;29(11): 2174-2183.
9. Okuno S, Sakurada K, Ohta H, Ikegaya H, Kazui Y, Akutsu T, Takatori T, Iwadate K. Blood-brain barrier penetration of novel pyridinealdoxime methiodide (PAM)-type oximes examined by brain microdialysis with LC-MS/MS. Toxicol Appl Pharmacol 2008;227(1):8-15.
10. Shih T-M, Skovira JW, O'Donnell JC, McDonough JH. Central acetylcholinesterase reactivation by oximes improves survival and terminates seizures following nerve agent intoxication. Adv Stud Biol 2009;1(3):155-196.
11. Skovira JW, O'Donnell JC, Koplovitz I, Kan RK, McDonough JH, Shih TM. Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs. Chem Biol Interact 2010;187(1-3):318-324.
12. Sit RK, Radic Z, Gerardi V, Zhang L, Garcia E, Katalinic M, Amitai G, Kovarik Z, Fokin VV, Sharpless KB, Taylor P. New structural scaffolds for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem 2011;286(22):19422-19430.
13. Radic Z, Sit RK, Kovarik Z, Berend S, Garcia E, Zhang L, Amitai G, Green C, Radic B, Fokin VV, Sharpless KB, Taylor P. Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem 2012;287(15):11798-11809.
14. Kalisiak J, Ralph EC, Cashman JR. Nonquaternary reactivators for organophosphate-inhibited cholinesterases. J Med Chem 2012;55(1):465-474.
15. Kalisiak J, Ralph EC, Zhang J, Cashman JR. Amidine-oximes: reactivators for organophosphate exposure. J Med Chem 2011;54(9):3319-3330.
16. Gray AP. Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Drug Metab Rev 1984;15(3):557-589.
17. Barakat NH, Zheng X, Gilley CB, MacDonald M, Okolotowicz K, Cashman JR, Vyas S, Beck JM, Hadad CM, Zhang J. Chemical synthesis of two series of nerve agent model compounds and their stereoselective interaction with human acetylcholinesterase and human butyrylcholinesterase. Chem Res Toxicol 2009;22(10):1669-1679.
18. Denton TT, Zhang X, Cashman JR. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 2004;67(4):751-756.
19. Denton TT, Zhang X, Cashman JR. 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem 2005;48(1):224-239.
20. Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, Ozers MS, Lebakken CS, Trubetskoy OV. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate. Assay Drug Dev Technol 2002;1(1 Pt 1):73-81.
21. Ellman GL, Courtney KD, Andres V, Jr., Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
22. O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000;267(17):5421-5426.
23. Chen S, Zhang J, Lumley L, Cashman JR. Immunodetection of serum albumin adducts as biomarkers for organophosphorus exposure. J Pharmacol Exp Ther 2013;344(2):531-541.
24. Mazak K, Noszal B. Zwitterions can be predominant in membrane penetration of drugs: experimental proof. J Med Chem 2012.
25. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: Concepts and applications. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
26. Ellin RI, Carlese JS, Kondritzer AA. Stability of pyridine-2-aldoxime methiodide. II. Kinetics of deterioration in dilute aqueous solutions. J Pharm Sci 1962;51:141-146.
27. Hoffman RS, Mercurio-Zappala M, Bouchard N, Ravikumar P, Goldfrank L. Preparing for Chemical Terrorism: A Study of the Stability of Expired Pralidoxime (2-PAM). Disaster Med Public Health Prep 2012;6(1):20-25.
28. Pohanka M, Novotny L, Fusek J, Pikula J. HI-6 and obidoxime implication in oxidative stress, antioxidants level and apoptosis. Afr J Pharm Pharmacol 2011;5(8):1145-1149.
29. American Society of Hospital Pharmacists. AHFS drug information. Bethesda, MD: Published by authority of the Board of Directors of the American Society of Hospital Pharmacists; 1989. p v.
30. Erdmann WD, Engelhard H. [Pharmacologic-toxicologic studies with the dichloride of bis-(4-hydroxy-iminomethyl-1-pyridinium-methyl)-ether, a new esterase reactivator]. Arzneimittelforschung 1964;14:5-11.